D. E. Shaw & Co., Inc.
- SEC CIK
- 0001009207
- Latest filing
- Aug 14, 2026
NTLA holding history
Intellia Therapeutics, Inc. in every 13F filed by D. E. Shaw & Co., Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
NTLA overviewAll 13F holders of NTLAFull Q2 2026 holdings
- Shares (Q2 2026)
- 6,443,323
- Value
- $109.0M
- % of portfolio
- 0.1%
- Quarters held
- 16
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 6,443,323 | $109.0M | 0.1% | +715,146+12.5% | Added | Holders |
| Q1 2026 | 5,728,177 | $73.4M | 0.1% | +397,113+7.4% | Added | Holders |
| Q4 2025 | 5,331,064 | $47.9M | <0.1% | +3,102,664+139.2% | Added | Holders |
| Q3 2025 | 2,228,400 | $38.5M | <0.1% | +1,403,673+170.2% | Added | Holders |
| Q2 2025 | 824,727 | $7.74M | <0.1% | +792,331+2,445.8% | Added | Holders |
| Q1 2025 | 32,396 | $230.3K | <0.1% | −1,187−3.5% | Reduced | Holders |
| Q4 2024 | 33,583 | $391.6K | <0.1% | +21,303+173.5% | Added | Holders |
| Q3 2024 | 12,280 | $252.4K | <0.1% | +12,280 | New | Holders |
| Q1 2023 | 0 | $0 | 0.0% | −15,152−100.0% | Sold out | Holders |
| Q4 2022 | 15,152 | $528.7K | <0.1% | −36,419−70.6% | Reduced | Holders |
| Q3 2022 | 51,571 | $2.89M | <0.1% | −374,779−87.9% | Reduced | Holders |
| Q2 2022 | 426,350 | $22.1M | <0.1% | +207,941+95.2% | Added | Holders |
| Q1 2022 | 218,409 | $15.9M | <0.1% | +215,775+8,191.9% | Added | Holders |
| Q4 2021 | 2,634 | $311.0K | <0.1% | −7,398−73.7% | Reduced | Holders |
| Q3 2021 | 10,032 | $1.35M | <0.1% | −104,960−91.3% | Reduced | Holders |
| Q2 2021 | 114,992 | $18.6M | <0.1% | −288,728−71.5% | Reduced | Holders |
| Q1 2021 | 403,720 | $32.4M | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.